Table 2 Association between heparin use and clinic outcomes in patients with acute pancreatitis.
Outcome | Original cohort | Matched cohort | ||||||
|---|---|---|---|---|---|---|---|---|
No heparin (n = 320) | Early heparin (n = 532) | HR (95% CI) | P-value | No heparin (n = 273) | Early heparin (n = 273) | HR (95% CI) | P-value | |
Primary outcome | ||||||||
28-day mortality, n (%) | 52 (16.25%) | 55 (10.34%) | 0.62 (0.42–0.90) | 0.022 | 40 (14.65%) | 25 (9.16%) | 0.61 (0.37–0.99) | 0.044 |
Secondary outcomes | ||||||||
180-day mortality, n (%) | 88 (27.50%) | 98 (18.4%) | 0.64 (0.48–0.85) | 0.002 | 70 (25.64) | 46 (16.85%) | 0.62 (0.44–0.89) | 0.009 |
In-hospital mortality, n (%) | 53 (16.56%) | 55 (10.34%) | 0.60 (0.41–0.88) | 0.009 | 41 (15.02%) | 25 (9.16%) | 0.59 (0.36–0.96) | 0.034 |
Length of hospital stay, median (IQR) | 13.62 (7.35, 24.72) | 11.41 (6.61, 22.10) | 0.060 | 13.07 (7.09, 22.71) | 11.55 (6.78, 22.63) | 0.395 | ||
Length of ICU stay, median (IQR) | 2.92 (1.70, 6.61) | 3.11 (1.83, 7.65) | 0.150 | 2.78 (1.70, 6.50) | 3.04 (1.82, 7.00) | 0.415 | ||
